Skip to main content

$0.375 0.005 (1.35%)

High

$0.38

Low

$0.38

Trades

2

Turnover

$1,293

Volume

3,448
30 June 2023 at 10:43am
Register to track AGN and receive email alerts.

Non-Dilutive Funding Received to Progress Alzheimers Studies

StockBot

416,823 posts

AGN released this announcement to the ASX on 22 February 2023, 8:06. The announcement is marked as price sensitive, and is 2 page(s) in length and 205.26kb in size.

You can view all announcements from AGN and see how they appear on a price chart on the announcements page.

At the date of this announcement, AGN was 0.000% short sold according to ASIC data. It was ranked the 653rd most shorted stock on the ASX. It is now ranked as the 595th most shorted stock on the ASX with 0.001% of total shares short sold as of the latest reported data (16 August 2024).

Other Recent Announcements from AGN
ARG-007 Protects Brain Cells in Moderate TBI Model 22 June 2023, 8:19
Becoming a substantial holder 20 June 2023, 8:21
Becoming a substantial holder 13 June 2023, 17:34
Non-Dilutive Funding Received to Progress Alzheimers Studies 22 February 2023, 8:06
Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers 9 February 2023, 8:16
Investor Presentation 2 February 2023, 8:19
Quarterly Activities/Appendix 4C Cash Flow Report 31 January 2023, 7:42
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track AGN and receive email alerts.